Experience With Anifrolumab In Systemic Lupus Erythematosus Patients With Neurological Manifestations

This study examines the use of Anifrolumab in 3 female patients with systemic lupus erythematosus (SLE) and neurological manifestations. Anifrolumab, typically not used in such cases during clinical trials, showed mixed results. In Case 1, a 29-year-old woman achieved disease remission and stopped corticosteroids after 6 months. Case 2 experienced adverse effects, including thrombocytopenia and a cerebrovascular event, leading to discontinuation of Anifrolumab. Case 3 achieved disease remission and did not require steroid pulses for 6 months. While Anifrolumab reduced corticosteroid use and managed lupus headaches, safety concerns necessitate further research on its use in patients with neurological involvement.